T1	Competing_trial 0 80	Treatment with any investigational drug within 30 days of entry to this protocol
T2	Drug 105 116	Telbivudine
T3	Condition 125 134	hepatitis
T4	Qualifier 118 124	Severe
R1	Has_qualifier Arg1:T3 Arg2:T4	
T5	Measurement 161 164	ALT
T6	Value 164 173	>10 x ULN
R2	Has_value Arg1:T5 Arg2:T6	
R3	AND Arg1:T3 Arg2:T5	
T7	Condition 200 209	cirrhosis
T8	Qualifier 186 199	decompensated
R4	Has_qualifier Arg1:T7 Arg2:T8	
T9	Condition 222 230	jaundice
T10	Condition 250 259	cirrhosis
T11	Condition 261 268	ascites
T12	Condition 270 286	bleeding gastric
T13	Condition 290 308	esophageal varices
T14	Condition 312 326	encephalopathy
*	OR T12 T13 T14
T15	Scope 211 326	defined as jaundice in the presence of cirrhosis, ascites, bleeding gastric or esophageal varices or encephalopathy
R5	Subsumes Arg1:T7 Arg2:T15	
T16	Condition 342 353	neutropenia
T17	Qualifier 329 341	Pre-existent
R6	Has_qualifier Arg1:T16 Arg2:T17	
T18	Measurement 355 366	neutrophils
T19	Value 367 377	<1,500/mm3
R7	Has_value Arg1:T18 Arg2:T19	
T20	Condition 382 398	thrombocytopenia
T21	Measurement 400 409	platelets
T22	Value 410 422	< 90,000/mm3
R8	Has_value Arg1:T21 Arg2:T22	
R9	AND Arg1:T20 Arg2:T21	
R10	AND Arg1:T16 Arg2:T18	
*	OR T16 T20
T23	Qualifier 443 460	hepatitis C virus
T24	Qualifier 462 479	hepatitis D virus
T25	Qualifier 483 511	human immunodeficiency virus
T26	Qualifier 513 516	HIV
T27	Condition 425 437	Co-infection
*	OR T23 T24 T25
R11	Subsumes Arg1:T25 Arg2:T26	
T28	Scope 443 516	hepatitis C virus, hepatitis D virus or human immunodeficiency virus (HIV
R12	Has_scope Arg1:T27 Arg2:T28	
T29	Condition 557 570	liver disease
T30	Qualifier 537 546	inherited
T31	Qualifier 525 533	acquired
*	OR T30 T31
T32	Scope 525 546	acquired or inherited
R13	Has_scope Arg1:T29 Arg2:T32	
T33	Condition 572 595	alcoholic liver disease
T34	Condition 597 626	obesity induced liver disease
T35	Condition 628 654	drug related liver disease
T36	Condition 656 677	auto-immune hepatitis
T37	Condition 679 694	hemochromatosis
T38	Condition 696 712	Wilson's disease
T39	Condition 716 746	alpha-1 antitrypsin deficiency
*	OR T33 T34 T35 T36 T37 T38 T39
T40	Scope 572 745	alcoholic liver disease, obesity induced liver disease, drug related liver disease, auto-immune hepatitis, hemochromatosis, Wilson's disease or alpha-1 antitrypsin deficienc
R14	Subsumes Arg1:T29 Arg2:T40	
T41	Measurement 748 765	Alpha fetoprotein
T42	Value 766 776	> 50 ng/ml
R15	Has_value Arg1:T41 Arg2:T42	
T43	Condition 788 802	hypothyroidism
T44	Condition 778 783;792 802	Hyper thyroidism
*	OR T43 T44
T45	Drug 823 833	medication
T46	Non-query-able 804 939	subjects requiring medication to maintain TSH levels in the normal range are eligible if all other inclusion/exclusion criteria are met
T47	Procedure 942 970	Immune suppressive treatment
T48	Temporal 971 999	within the previous 6 months
R16	Has_temporal Arg1:T47 Arg2:T48	
T49	Condition 1001 1019	Contra-indications
T50	Drug 1024 1047	alfa-interferon therapy
T51	Condition 1063 1079	hypersensitivity
T52	Drug 1083 1093	interferon
T53	Drug 1097 1110	Peginterferon
T54	Non-query-able 1114 1239	any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study
*	OR T52 T53
T55	Scope 1083 1110	interferon or Peginterferon
R17	Has_scope Arg1:T51 Arg2:T55	
R18	AND Arg1:T49 Arg2:T50	
R19	Subsumes Arg1:T49 Arg2:T51	
T56	Pregnancy_considerations 1242 1267	Pregnancy, breast-feeding
T57	Qualifier 1275 1286	significant
T58	Condition 1287 1302	medical illness
R20	Has_qualifier Arg1:T58 Arg2:T57	
T59	Qualifier 1341 1352	significant
T60	Condition 1353 1374	pulmonary dysfunction
T61	Temporal 1375 1399	in the previous 6 months
T62	Condition 1401 1411	malignancy
T63	Negation 1412 1422	other than
T64	Condition 1423 1450	skin basocellular carcinoma
T65	Temporal 1451 1470	in previous 5 years
T66	Condition 1472 1498	immunodeficiency syndromes
T67	Condition 1505 1519	HIV positivity
T68	Condition 1521 1541	auto-immune diseases
T69	Procedure 1543 1560	organ transplants
T70	Negation 1561 1571	other than
T71	Procedure 1572 1578;1588 1598	cornea transplant
T72	Procedure 1583 1598	hair transplant
*	OR T72 T71
T73	Scope 1572 1598	cornea and hair transplant
R21	Has_negation Arg1:T73 Arg2:T70	
T74	Scope 1543 1598	organ transplants other than cornea and hair transplant
*	OR T68 T67 T74
T75	Scope 1505 1598	HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant
R22	Subsumes Arg1:T66 Arg2:T75	
R23	Has_negation Arg1:T64 Arg2:T63	
T76	Scope 1401 1470	malignancy other than skin basocellular carcinoma in previous 5 years
R24	Has_temporal Arg1:T76 Arg2:T65	
R25	Has_qualifier Arg1:T60 Arg2:T59	
R26	Has_temporal Arg1:T60 Arg2:T61	
*	OR T60 T76 T66
T77	Scope 1341 1598	significant pulmonary dysfunction in the previous 6 months, malignancy other than skin basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant
R27	Subsumes Arg1:T58 Arg2:T77	
T78	Drug 1663 1671;1690 1698	systemic steroids
T79	Qualifier 1655 1662	chronic
R28	Has_qualifier Arg1:T78 Arg2:T79	
T80	Temporal 1700 1730	during the course of the study
R29	Has_temporal Arg1:T78 Arg2:T80	
T81	Reference_point 1711 1730	course of the study
R30	Has_index Arg1:T80 Arg2:T81	
T82	Condition 1732 1747	Substance abuse
T83	Qualifier 1757 1764	alcohol
T84	Qualifier 1778 1788	I.V. drugs
T85	Qualifier 1793 1806	inhaled drugs
T86	Temporal 1807 1827	in the past 2 years.
*	OR T83 T84 T85
T87	Multiplier 1766 1775	>80 g/day
R31	Has_multiplier Arg1:T83 Arg2:T87	
T88	Scope 1757 1806	alcohol (>80 g/day), I.V. drugs and inhaled drugs
R32	Has_scope Arg1:T82 Arg2:T88	
R33	Has_temporal Arg1:T82 Arg2:T86	
T89	Non-query-able 1829 2017	Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the study
